01.16.19
PCAS and all NOVACAP subsidiaries have unified their names into a new one and become SEQENS.
SEQENS is an integrated global leader in specialty ingredients and pharmaceutical synthesis, operating 24 manufacturing plants and three R&D centers in Europe, North America and Asia with 3,200 employees. More than 300 scientists, engineers and experts develop tailor-made solutions for customers and ensure that products are successfully transferred into production.
SEQENS refers to the company’s core synthesis activities, mixed with that sequencing idea in which the company arranges molecules, competencies and technologies.
In the electronic industry, SEQENS supports its customers for the development, the scale-up and the manufacturing of polymers and complex molecules used in semiconductor photolithography processes and for organic electronic devices, such as OLED , OPV, O-TFT and OPD. SEQENS provides photoresist polymers and additives with low metal content, at the ppb or ppt level, and quality control.
In the pharmaceutical industry, SEQENS supports its customers for the development, the scale-up and the manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products.
“As SEQENS, we intend to stand as a strong, global and integrated player in specialty ingredients and pharmaceutical synthesis. Our mission is to bring R&D and industrial performance to our clients’ projects,” said SEQENS CEO Pierre Luzeau.
SEQENS is an integrated global leader in specialty ingredients and pharmaceutical synthesis, operating 24 manufacturing plants and three R&D centers in Europe, North America and Asia with 3,200 employees. More than 300 scientists, engineers and experts develop tailor-made solutions for customers and ensure that products are successfully transferred into production.
SEQENS refers to the company’s core synthesis activities, mixed with that sequencing idea in which the company arranges molecules, competencies and technologies.
In the electronic industry, SEQENS supports its customers for the development, the scale-up and the manufacturing of polymers and complex molecules used in semiconductor photolithography processes and for organic electronic devices, such as OLED , OPV, O-TFT and OPD. SEQENS provides photoresist polymers and additives with low metal content, at the ppb or ppt level, and quality control.
In the pharmaceutical industry, SEQENS supports its customers for the development, the scale-up and the manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products.
“As SEQENS, we intend to stand as a strong, global and integrated player in specialty ingredients and pharmaceutical synthesis. Our mission is to bring R&D and industrial performance to our clients’ projects,” said SEQENS CEO Pierre Luzeau.
